Andrographolide
| Names | |
|---|---|
| IUPAC name
3-[2-[Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-napthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.024.411 |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C20H30O5 | |
| Molar mass | 350.455 g·mol−1 |
| Appearance | Rhombic prisms or plates from ethanol or methanol |
| Density | 1.2317 g/cm3 |
| Melting point | 230 to 231 °C (446 to 448 °F; 503 to 504 K) |
| Sparingly soluble | |
| Related compounds | |
Related labdanes
|
14-deoxyandrographolide |
Related compounds
|
Xiyanping |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Andrographolide is a labdane diterpenoid that has been isolated from the stem and leaves of Andrographis paniculata. Andrographolide is an extremely bitter substance.
Andrographolide has been studied for its effects on cell signaling, immunomodulation, and stroke. Study has shown that andrographolide may bind to a spectrum of protein targets including NF-κB and actin by covalent modification.
Andrographolide is a non-ATP-competitive, substrate-competitive GSK-3β inhibitor. When the substrate concentration is 25μM, the IC50 of andrographolide for GSK-3β is 5.58±0.40μM. When the substrate concentration is increased to 90μM, the IC50 increases to 37.7μM.